Singapore medical journal · 2026
Suboptimal response to ursodeoxycholic acid among patients with primary biliary cholangitis and fenofibrate as add-on therapy: a single-centre retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khamis Farahani, Teoh E-Shing, Chan Wah-Kheong
Аннотация
INTRODUCTION: Ursodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cholangitis. We aimed to determine the prevalence of suboptimal response to UDCA and to examine the use of fenofibrate as an add-on therapy.
METHODS: This was a retrospective study on all patients with primary biliary cholangitis seen at Gastroenterology and Hepatology Clinic between January 2019 and December 2024.
RESULTS: Data for 59 patients were analysed (median age 62.5 [range 51.0-72.3] years, 78.0% female). More than half (54.2%) of the patients had suboptimal response (i.e. failure to achieve alkaline phosphatase [ALP] ≤1.67 times the upper limit of normal [ULN], total bilirubin less than ULN and ALP decreased by ≥15%) after 1 year of UDCA. Among them, 73.1% continued UDCA monotherapy, whereas the remaining 26.9% received fenofibrate add-on therapy. A significantly greater proportion of patients who received fenofibrate add-on therapy achieved biochemical response (83.3% vs. 14.3%, P = 0.003), ALP normalisation (66.7% vs. 14.3%, P = 0.019) and deep response (i.e. ALP normalisation and total bilirubin ≤0.6 ULN) (33.3% vs. 0%, P = 0.023) compared with patients who continued UDCA monotherapy. After a median follow-up of 56 (19-122) months, seven patients developed cirrhosis, eight patients developed decompensated cirrhosis and three patients had liver-related mortality. There were no liver-related events among patients who achieved a biochemical response after 1 year of UDCA therapy and among patients who were on fenofibrate add-on therapy.
CONCLUSION: Suboptimal response to UDCA is common among patients with primary biliary cholangitis, and fenofibrate add-on therapy can improve biochemical response in these patients.
METHODS: This was a retrospective study on all patients with primary biliary cholangitis seen at Gastroenterology and Hepatology Clinic between January 2019 and December 2024.
RESULTS: Data for 59 patients were analysed (median age 62.5 [range 51.0-72.3] years, 78.0% female). More than half (54.2%) of the patients had suboptimal response (i.e. failure to achieve alkaline phosphatase [ALP] ≤1.67 times the upper limit of normal [ULN], total bilirubin less than ULN and ALP decreased by ≥15%) after 1 year of UDCA. Among them, 73.1% continued UDCA monotherapy, whereas the remaining 26.9% received fenofibrate add-on therapy. A significantly greater proportion of patients who received fenofibrate add-on therapy achieved biochemical response (83.3% vs. 14.3%, P = 0.003), ALP normalisation (66.7% vs. 14.3%, P = 0.019) and deep response (i.e. ALP normalisation and total bilirubin ≤0.6 ULN) (33.3% vs. 0%, P = 0.023) compared with patients who continued UDCA monotherapy. After a median follow-up of 56 (19-122) months, seven patients developed cirrhosis, eight patients developed decompensated cirrhosis and three patients had liver-related mortality. There were no liver-related events among patients who achieved a biochemical response after 1 year of UDCA therapy and among patients who were on fenofibrate add-on therapy.
CONCLUSION: Suboptimal response to UDCA is common among patients with primary biliary cholangitis, and fenofibrate add-on therapy can improve biochemical response in these patients.